Rigel Pharmaceuticals reported $1.04M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Agenus AGEN:US $ 543K 338K
Amgen AMGN:US $ 1510M 51M
Anika Therapeutics ANIK:US $ 14.8M 0.09M
AstraZeneca AZN:LN 1904M 375M
Astrazeneca AZN:US 1.9B 375M
Biomarin Pharmaceutical BMRN:US $ 123.13M 6.16M
Bristol Myers Squibb BMY:US $ 2677M 206M
ChemoCentryx CCXI:US 205K 97K
Daiichi Sankyo 4568:JP Y 74798M 14032M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Halozyme Therapeutics HALO:US $ 15.92M 5.66M
Heron Therapeutics HRTX:US $ 11.36M 0.41M
Intrexon XON:US $ 17.1M 2.17M
Karyopharm Therapeutics KPTI:US $ 939K 487K
Ligand Pharmaceuticals LGND:US $ 4.7M 7.28M
MacroGenics MGNX:US 48K 899K
Neurocrine Biosciences NBIX:US $ 4.8M 0.2M
Pfizer PFE:US $ 8671M 1339M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Rigel Pharmaceuticals RIGL:US $ 1.04M 0.92M
Ultragenyx Pharmaceutical RARE:US $ 8.27M 2.17M
Veracyte VCYT:US $ 25.03M 1.32M